Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTL0016878 CSF and Plasma PK Study in Healthy Males
NCT04849286Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Sep 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of direclidine in schizophrenia and Alzheimer's disease (AD) (4 arms), sponsored by Nxera Pharma. Primary endpoints: Concentration of HTL0016878 in CSF at 6 hours, Concentration of HTL0016878 in plasma Cmax and 1 more. Started Sep 2018; status: completed.
02
Drugs
direclidine
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04849286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849286.